Direct comparison of dietary portfolio vs statin on C-reactive protein

D J A Jenkins, C W C Kendall, A Marchie, D A Faulkner, A R Josse, J M W Wong, R de Souza, A Emam, T L Parker, T J Li, R G Josse, L A Leiter, W Singer, P W Connelly, D J A Jenkins, C W C Kendall, A Marchie, D A Faulkner, A R Josse, J M W Wong, R de Souza, A Emam, T L Parker, T J Li, R G Josse, L A Leiter, W Singer, P W Connelly

Abstract

Background: 3-Hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) markedly reduce serum cholesterol and have anti-inflammatory effects. The effect of cholesterol-lowering diets on inflammatory biomarkers is less well known.

Objective: To compare the efficacy of a dietary combination (portfolio) of cholesterol-lowering foods vs a statin in reducing C-reactive protein (CRP) as a biomarker of inflammation linked to increased cardiovascular disease risk.

Methods: In all, 34 hyperlipidemic subjects completed three 1-month treatments as outpatients in random order: a very low-saturated fat diet (control); the same diet with 20 mg lovastatin (statin); and a diet high in plant sterols (1.0 g/1000 kcal), soy protein (21.4 g/1000 kcal), viscous fibers (9.8 g/1000 kcal), and almonds (14 g/1000 kcal) (portfolio). Fasting blood samples were obtained at weeks 0, 2, and 4.

Results: Using the complete data, no treatment reduced serum CRP. However, when subjects with CRP levels above the 75th percentile for previously reported studies (> 3.5 mg/l) were excluded, CRP was reduced similarly on both statin, -16.3 +/- 6.7% (n = 23, P = 0.013) and dietary portfolio, -23.8 +/- 6.9% (n = 25, P = 0.001) but not the control, 15.3 +/- 13.6% (n = 28, P = 0.907). The percentage CRP change from baseline on the portfolio treatment (n = 25) was greater than the control (n = 28, P = 0.004) but similar to statin treatment (n = 23, P = 0.349). Both statin and portfolio treatments were similar in reducing CRP and numerically more effective than control but only the change in portfolio was significant after the Bonferroni adjustment.

Conclusions: A combination of cholesterol-lowering foods reduced C-reactive protein to a similar extent as the starting dose of a first-generation statin.

Figures

Figure 1
Figure 1
Flow diagram showing progress of patient through the trial.
Figure 2
Figure 2
Mean C-reactive protein concentrations at week 0, 2, and 4 in the 34 subjects who completed all three treatments. Only subjects with values ≤3.5 mg/l for weeks 0, 2, 4 were included in the analysis. (Control, n=25; Statin, n=23; and Portfolio, n=23).

References

    1. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003;107:443–447. doi: 10.1161/.
    1. Albert MA, Glynn RJ, Ridker PM. Effect of physical activity on serum C-reactive protein. Am. J. Cardiol. 2004;93:221–225. doi: 10.1016/j.amjcard.2003.09.046.
    1. Blok WL, Deslypere JP, Demacker PN, van der Ven-Jongekrijg J, Hectors MP, van der Meer JW, Katan MB. Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. Eur. J. Clin. Invest. 1997;27:1003–1008. doi: 10.1046/j.1365-2362.1997.2240775.x.
    1. Box GEP, Cox DR. An analysis of transformation. JR. Stat. Soc. (B) 1964;26:211–252.
    1. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulinresistance, diabetes and cardiovascular disease: the common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. 2004;24:816–823. doi: 10.1161/01.ATV.0000122852.22604.78.
    1. Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment. Thromb. Haemost. 2000;83:549–553. doi: 10.1055/s-0037-1613861.
    1. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100:717–722. doi: 10.1161/01.CIR.100.7.717.
    1. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004;350:1387–1397. doi: 10.1056/NEJMoa032804.
    1. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J. Am. Coll. Cardiol. 1999;33:1294–1304. doi: 10.1016/S0735-1097(99)00018-2.
    1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM., Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–1622. doi: 10.1001/jama.279.20.1615.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001): Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285, 2486–2497.
    1. Ford ES. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care. 1999;22:1971–1977. doi: 10.2337/diacare.22.12.1971.
    1. Foster-Powell K, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values: 2002. Am. J. Clin. Nutr. 2002;76:5–56. doi: 10.1093/ajcn/76.1.5.
    1. Frohlich M, Sund M, Lowel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95) Eur. Heart J. 2003;24:1365–1372. doi: 10.1016/S0195-668X(03)00260-4.
    1. Heart Protection Study Collaborative Group (2002): MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22.
    1. Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, Bittner V, Schrott HG, Blumenthal RS, Levy R. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) Circulation. 2002;105:2962–2967. doi: 10.1161/01.CIR.0000019406.74017.B2.
    1. Jenkins DJ, Kendall CW, Connelly PW, Jackson CJ, Parker T, Faulkner D, Vidgen E. Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. Metabolism. 2002;51:919–924. doi: 10.1053/meta.2002.33352.
    1. Jenkins DJ, Kendall CW, Faulkner D, Vidgen E, Trautwein EA, Parker TL, Marchie A, Koumbridis G, Lapsley KG, Josse RG, Leiter LA, Connelly PW. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism. 2002;51:1596–1604. doi: 10.1053/meta.2002.35578.
    1. Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W, Haight JS, Faulkner D, Vidgen E, Lapsley KG, Spiller GA. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. Circulation. 2002;106:1327–1332. doi: 10.1161/01.CIR.0000028421.91733.20.
    1. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA, Connelly PW. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502–510. doi: 10.1001/jama.290.4.502.
    1. Jenkins DJ, Kendall CW, Marchie A, Faulkner D, Wong J, de Sousa R, Emam A, Parker T, Vidgen E, Trautwein E, Lapsley K, Josse RG, Leither LA, Singer W, Connelly PW. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am. J. Clin. Nutr. 2005;81:380–387. doi: 10.1093/ajcn.81.2.380.
    1. Jenkins DJ, Wolever TM, Leeds AR, Gassull MA, Haisman P, Dilawari J, Goff DV, Metz GL, Alberti KG. Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity. BMJ. 1978;27:1392–1394. doi: 10.1136/bmj.1.6124.1392.
    1. Kalela A, Laaksonen R, Lehtimaki T, Koivu TA, Hoyhtya M, Janatuinen T, Pollanen P, Vesalainen R, Saikku P, Knuuti J, Nikkari ST. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am. J. Cardiol. 2001;88:173–175. doi: 10.1016/S0002-9149(01)01616-2.
    1. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin. Chem. 2003;49:1258–1271. doi: 10.1373/49.8.1258.
    1. Lemieux I, Pascot A, Prud’homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 2001;21:961–967. doi: 10.1161/01.ATV.21.6.961.
    1. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am. J. Clin. Nutr. 2002;75:492–498. doi: 10.1093/ajcn/75.3.492.
    1. Neter J, Wasserman W, Kutner MH. Applied Linear Statistical Models. 1985.
    1. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin. Chem. 2001;47:444–450.
    1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511. doi: 10.1161/01.CIR.0000052939.59093.45.
    1. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108:155–160. doi: 10.1161/01.CIR.0000079224.46084.C2.
    1. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288:980–987. doi: 10.1001/jama.288.8.980.
    1. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J. Hypertens. 2003;21:1787–1803. doi: 10.1097/00004872-200310000-00002.
    1. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–733. doi: 10.1161/01.CIR.98.8.731.
    1. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011. doi: 10.1161/01.CIR.97.20.2007.
    1. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713–716. doi: 10.1161/01.CIR.100.7.713.
    1. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM., Jr Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 2001;344:1959–1965. doi: 10.1056/NEJM200106283442601.
    1. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002;347:1557–1565. doi: 10.1056/NEJMoa021993.
    1. Rifai N, Ridker PM. Inflammatory markers and coronary heart disease. Curr. Opin. Lipidol. 2002;13:383–389. doi: 10.1097/00041433-200208000-00005.
    1. Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin. Chem. 2003;49:666–669. doi: 10.1373/49.4.666.
    1. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893–1900. doi: 10.1161/01.CIR.102.16.1893.
    1. SAS Institute (1997): SAS/STAT User's Guide (ed 6.12). Cary, NC: SAS Institute.
    1. Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389.
    1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995;333:1301–1307. doi: 10.1056/NEJM199511163332001.
    1. Tall AR. C-reactive protein reassessed. N. Engl. J. Med. 2004;350:1450–1452. doi: 10.1056/NEJMe048020.
    1. Homocysteine Studies Collaboration Homocysteine and Risk of Ischemic Heart Disease and Stroke. JAMA. 2002;288(16):2015. doi: 10.1001/jama.288.16.2015.
    1. Tillet WS, Francis T. Serological reaction in pneumonia with a non-protein somatic fraction of pneumococcus. J. Exp. Med. 1930;52:561–571. doi: 10.1084/jem.52.4.561.
    1. Wolever TMS, Chiasson JL, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW & Ryan EA (2004): Effect of modifying source or amount of carbohydrate glucose and lipid control in type 2 diabetes. Can. J. Diab.48 (Suppl 1) (CDA abstract).
    1. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 1999;19:972–978. doi: 10.1161/01.ATV.19.4.972.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever